A novel insulin mimetic without a proliferative effect on vascular smooth muscle cells  by Weber, Michael A. et al.
1118
with DM and is characterized by loss of insulin secre-
tion that requires exogenous administration of
insulin.4 Clinically, this results in occasional periods
of hyperglycemia and relative hyperinsulinemia. Type
2, or non–insulin-dependent DM, affects approxi-
mately 90% of patients with DM and is characterized
The National Health Interview Survey conducted
by the National Institutes of Health estimated in
1991 that 7.2 million people in the United States
had diabetes, and the number has increased during
this decade.1-3 Type 1, or insulin-dependent diabetes
mellitus (DM), affects approximately 10% of patients
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Background: Insulin induces vascular smooth muscle cell (VSMC) proliferation, which is an
important step in the atherosclerotic process. Recently, a nonpeptidyl fungal metabolite orig-
inally referred to as L-783,281, but also known as demethylasterriquinone B-1 (DMAQB-
1), was found to have hypoglycemic activity in diabetic mice through interaction with the
intracellular β subunit of the insulin receptor. This study was designed to determine whether
DMAQB-1 has an insulin-like proliferative effect on human infragenicular VSMCs.
Methods: Human infragenicular VSMCs were isolated from diabetic patients undergoing
amputations. DMAQB-1 cell culture dose response was measured in both serum-free
media and media with 1% fetal bovine serum (FBS). A working concentration of
DMAQB-1 that ranged from 0.5 to 500 nmol/L was studied in the presence of varying
concentrations of glucose and insulin. The ability of DMAQB-1 to stimulate glucose
transport at less than or equal to 100 nmol/L was determined by [14C]-2-deoxyglucose
uptake. DNA synthesis was used as the marker for proliferative stimulus and detected by
[3H]-thymidine uptake measured at 24 hours. Analysis of variance was used to compare
the results among the groups; a P value less than .05 was considered significant.
Polynomial regression was used to calculate the median lethal dose.
Results: In normal glucose media (100 mg/dL), various concentrations of DMAQB-1
demonstrated a small but statistically significant decrease in DNA synthesis at 0.5 nmol/L
in serum-free media and at 5 nmol/L in media supplemented with 1% FBS. The corre-
sponding median lethal dose was 107 nmol/L in serum-free media and 650 nmol/L in
media supplemented with 1% FBS. A DMAQB-1 concentration of 5 nmol/L induced glu-
cose transport that was equivalent to an insulin concentration of 100 µU/mL. In serum-
free, high glucose media (200 mg/dL), DMAQB-1 concentrations up to 500 nmol/L did
not cause a statistically significant change in DNA synthesis. When serum-free, high glu-
cose media was combined with mild (100 µU/mL) or moderate (250 µU/mL) concen-
trations of insulin, DMAQB-1 caused no statistically significant increase in DNA synthesis.
Conclusion: Nontoxic doses of DMAQB-1 can induce glucose transport equivalent to
insulin in the physiologic range. However, DMAQB-1 does not have an insulin-like pro-
liferative effect on human VSMCs in normal-glucose, high-glucose, or high-insulin envi-
ronments. (J Vasc Surg 2000;32:1118-26.)
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by insulin receptor dysfunction or resistance.4 This
dysfunction also causes hyperglycemia and relative
hyperinsulinemia. In addition, it is not uncommon
for patients with type 2 DM to be managed with
exogenous insulin as their disease progresses.5
Therefore, diabetic patients are exposed to periods of
hyperglycemia, hyperinsulinemia, or both. In addi-
tion to its useful hypoglycemic effect, insulin causes
vascular smooth muscle cell (VSMC) proliferation.6,7
Also, the proliferative effects of glucose and insulin
have been shown to be additive in tissue culture.8
Thus, hyperglycemia and hyperinsulinemia have been
implicated in the development of atherosclerosis in
diabetic patients.9 Among other complications of
DM, atherosclerosis can lead to lifestyle-limiting
claudication, tissue loss, and amputation, in addition
to coronary artery disease and stroke.10
Recently, Zhang et al11 described a nonpeptidyl
fungal metabolite originally referred to as L-783,281,
but now named demethylasterriquinone B-1
(DMAQB-1), that caused insulin receptor (IR) activa-
tion. Using an IR tyrosine kinase assay with Chinese
hamster ovary cells that were manipulated to overex-
press human IR, they found that a 20-minute pulse of
DMAQB-1 at concentrations of 3 to 6 µmol/L
induced 50% of the maximal effect of insulin.11 Also,
these investigators observed that a pulse of DMAQB-
1 functioned as an insulin sensitizer at lower concen-
trations (0.6-2 µmol/L). Although a great deal of
homology exists between the IR and other protein
growth factor receptors, DMAQB-1 only weakly acti-
vated the epidermal growth factor receptor and the
insulin-like growth factor (IGF) receptor at concentra-
tions greater than 30 µmol/L.11,12 With the combi-
nation of receptor chimerism and recombinant
receptor kinase protein, the specificity of DMAQB-1
for the intracellular β subunit was established.11 Zhang
et al11 then showed that DMAQB-1 administered
orally could control blood glucose in diabetic mice.11
It has been shown that the proliferative effect of
insulin is caused by its cross-reactivity with the IGF-
1 receptor.13,14 Because of the specificity of
DMAQB-1 for the IR and the negligible avidity for
the IGF-1 receptor, we hypothesized that DMAQB-
1 may not have the same proliferative effect on
VSMCs as insulin does. Therefore, our study was
designed to measure DNA synthesis in human infra-
genicular VSMCs exposed to DMAQB-1 to detect if
an insulin-like proliferative stimulus exists.
MATERIALS AND METHODS
Cell harvesting, isolation, and characterization.
Segments of infragenicular arteries were harvested
from patients undergoing lower extremity amputa-
tions for end-stage peripheral vascular disease. All
donors were men aged between 55 and 70 years who
had type 2 DM. Prior consent was obtained in accor-
dance with the Medical Center’s Institutional Review
Board. After rinsing with phosphate-buffered saline
(PBS) (Gibco BRL, Grand Island, NY), we dissected
the adventitia, intima, and atherosclerotic plaque from
the arterial wall, leaving a layer of media. This layer was
minced and subjected to enzymatic dispersion with
0.8% collagenase and 0.05% elastase (Worthington
Biochemical Corporation, Freehold, NJ). The sample
was agitated in a water bath at 37°C for 3 hours. The
suspension was centrifuged at 2000 rpm for 2 minutes,
and the supernatant was removed. The pellet was
resuspended in enriched media that consisted of
Media-199 (M-199) (Gibco BRL) with 10% fetal
bovine serum (FBS) (Gibco BRL) and 1% antibiotic-
antimycotic (10,000 U/mL penicillin G sodium,
10,000 µU/mL streptomycin sulfate, and 25 µg/mL
amphotericin B) (Gibco BRL). The suspension was
transferred to vented culture flasks of 75 cm2 and incu-
bated at 37°C in 5% carbon dioxide until the cells grew
to confluence. The cultured cells were identified as
VSMCs with immunohistochemical staining for α-
smooth muscle actin, myosin, and vimentin as previ-
ously published.15 Passages 3 to 7 were used for all
subsequent experiments.
DNA synthesis assay. The VSMCs were pooled
to form a mixed culture and grown at 37°C in 5% car-
bon dioxide until they became confluent. Then, they
were trypsinized and seeded into 24 well plates at a
density of 50,000 cells per well. The cells were allowed
to attach and grow in enriched media (as above) until
they were subconfluent. The media was then replaced
with serum-free media that consisted of M-199 with
2% antibiotic-antimycotic for 48 hours to induce qui-
escence. Then, the cells were rinsed three times with
PBS, and the media was replaced with the tested con-
centrations of glucose, insulin, and DMAQB-1. The
cells were incubated at 37°C for 20 hours, at which
time [methyl-3H]-thymidine (2.5 µCi per well)
(Amerscham, Arlington Heights, Ill) was added. Four
hours later, the cells were rinsed three times with PBS.
Cell membranes were dissolved with 0.2 N of sodium
hyroxide, and the labeled DNA was precipitated with
10% trichloroacetic acid. The incorporated methyl-
tritium-thymidine was measured with a Beckman LS
6500 liquid scintillation counter. Values from six wells
were expressed as mean percentage decays per minute
± SEM as compared with controls from six wells.
Glucose transport assay. VSMCs were plated at a
concentration of 50,000 cells per well in fortified
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media and grown to subconfluence at 37°C in 5% car-
bon dioxide. The cells were rinsed three times with
cold PBS. The cells were incubated in serum-free M-
199 supplemented with 8 nmol/L of IGF-I
(Calbiochem, La Jolla, Calif) to deplete the wells of
residual insulin from the fortified media. IGF-I was
added to stimulate metabolism under serum- and
insulin-free conditions.16 After 24 hours, the cells were
rinsed three times with cold PBS and incubated with
physiologic saline solution (PSS) pH 7.4 that con-
tained 145 mmol/L of sodium chloride, 5 mmol/L 
of potassium chloride, 10 mmol/L of HEPES, 1
mmol/L of hydrated magnesium sulfate, 0.5 mmol/L
of disodium phosphate, and 1.5 mmol/L calcium
chloride.17 Cells were acclimatized in PSS for 2 hours,
after which the buffer was replaced with control PSS or
PSS containing insulin or DMAQB-1. The insulin
concentration tested was 100 µU/mL. The DMAQB-
1 concentrations tested were 0.5, 5, 10, 50, and 100
nmol/L. After 20 minutes of pretreatment, glucose
was added to each well to make a final glucose con-
centration of 100 mg/dL. Also, a tracer amount (0.2
µCi per well) of 1-[14C]-2-deoxyglucose (Sigma, St
Louis, Mo) was added. The cells were incubated for
24 hours and washed three times in cold PSS. The cell
membranes were dissolved with 0.5 mL of 0.5 N of
sodium hydroxide for 30 minutes, then neutralized
with 0.5 mL of 0.5 N of hydrochloric acid. The solu-
tion was transferred to scintillation vials, and 3 mL of
aqueous scintillation cocktail (Ultima Gold, Packard,
Meriden, Conn) was added. Glucose uptake was mea-
sured with a Beckman LS 6500 liquid scintillation
counter. Values were expressed as mean percentage
decays per minute ± SEM as compared with controls.
The means from 10 experimental wells in each group
were compared with those from 10 control wells.
Dose response. VSMCs were plated at a concen-
tration of 50,000 cells per well. The cells were rinsed
three times in cold PBS after attaching in fortified
media for 48 hours. Then, they were incubated in
serum-free M-199 with increasing concentrations of
DMAQB-1 from 0.5 nmol/L to 1 µmol/L. DNA
synthesis was detected by measuring labeled thymi-
dine incorporation, as previously described. M-199
supplemented with 1% FBS was also studied to
address the possibility of acute agent toxicity in
serum-free media. We chose 1% FBS because we have
previously shown that it maintained cell viability but
did not cause a statistically significant increase in cell
population over 6 days.2 Increasing concentrations of
Fig 1. A, Dose response in normoglycemic, serum-free media. Asterisk indicates P < .05 versus control con-
taining no DMAQB-1. B, Dose response in normal glucose media with 1% FBS. Asterisk indicates P < .05
versus control containing no DMAQB-1.
A B
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DMAQB-1 that ranged from 0.5 nmol/L to 1
µmol/L were added, and DNA synthesis was
detected by measuring labeled thymidine incorpora-
tion, as previously described.
High glucose alone and high glucose with
insulin. VSMCs were transferred to 24 well culture
plates at a concentration of 50,000 cells per well.
The cells were allowed to attach for 48 hours in for-
tified media. Next, the cells were washed with cold
PBS three times. Then, the cells were grown in
serum-free M-199 with a total glucose concentra-
tion of 200 mg/dL with increasing concentrations
of DMAQB-1 from 0.5 to 500 nmol/L. Various
amounts of insulin were added to create three
groups: no insulin, 100 µU/mL insulin, and 250
µU/mL insulin. DNA synthesis was detected by
measuring labeled thymidine incorporation, as previ-
ously described.
Statistical analysis. Statistical analysis was per-
formed with Sigmastat software (Jandel Scientific,
San Rafael, Calif). Because the results consist of mul-
tiple groups of continuous data, analysis of variance
was used to compare the results of 2-deoxyglucose
and thymidine incorporation. Statistical significance
was identified as a P value less than .05. To compare
the toxic range in serum-free media with 1% FBS
media, we analyzed the data with polynomial regres-
sion (Sigmastat; Jandel Scientific) to calculate the
median lethal dose (LD50).
RESULTS
Immunohistochemistry. The VSMCs displayed
characteristic cytoskeletal proteins by exhibiting
strong fluorescence of secondary antibodies when
primary antibodies against α-smooth muscle actin,
myosin, and vimentin were present. Cells in the
absence of primary antibodies demonstrated only
faint background fluorescence, which indicated the
high specificity of the secondary antibodies.
Dose response. Under the experimental condi-
tions of serum-free, normal glucose (100 mg/dL glu-
cose) media, 24-hour exposure to increasing
concentrations of DMAQB-1 from 0.5 nmol/L to 1
µmol/L did not cause an increase in thymidine incor-
poration. The acute sensitivity of VSMCs to
DMAQB-1 under these conditions was detected by
measuring a statistically significant 28% decrease in
labeled thymidine incorporation at the lowest con-
centration studied, 0.5 nmol/L (P < .05). Over the
next two concentrations studied, which represented a
100-fold increase in DMAQB-1 concentration, the
percentage thymidine incorporation formed a plateau.
At a DMAQB-1 concentration of 500 nmol/L,
which represented a 1000-fold increase over the low-
Fig 2. Glucose transport in normal glucose, serum-free media. Asterisk indicates P value < .05 versus con-
trol containing no DMAQB-1.
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est concentration tested, severe toxicity was detected
(P < .05). This concentration of DMAQB-1 caused
the thymidine incorporation to fall to 1%, as com-
pared with controls. With polynomial regression, the
calculated LD50 for DMAQB-1 in experimental nor-
mal glucose, serum-free media was 107 nmol/L. This
dose-response is illustrated in Fig 1, A.
Under the conditions of normal glucose media
supplemented with 1% FBS, no significant increase
in thymidine incorporation was measured. Although
there was a significant decrease in thymidine incor-
poration at 5 nmol/L, severe toxicity was only
detected at a concentration greater than 500 nmol/L.
With polynomial regression, the calculated LD50 for
DMAQB-1 in normal glucose, 1% FBS media is 650
nmol/L. Compared with serum-free media, the
addition of 1% FBS caused a sixfold favorable
increase in the LD50. This dose-response is illus-
trated in Fig 1, B.
Glucose transport. We measured glucose uptake
in normal glucose serum-free media to determine if
DMAQB-1 stimulated significant glucose uptake over
the range less than the LD50. Even at the lowest con-
centration of DMAQB-1 tested (0.5 nmol/L), an
increase was measured. At 5 nmol/L, the increase in
glucose incorporation became statistically significant
(P < .05). The glucose uptake continued to increase
and formed a plateau at a DMAQB-1 concentration
of 10 nmol/L. To correlate the effect of DMAQB-1
with insulin, we measured the glucose uptake induced
by 100 µU/mL of insulin. This level of insulin stim-
ulated a statistically significant 23% increase in glucose
uptake that was equivalent to the glucose uptake stim-
ulated by 5 nmol/L of DMAQB-1. Glucose uptake is
illustrated in Fig 2.
Effect in high-glucose conditions. Under the
experimental conditions of serum-free, high-glucose
(200 mg/dL glucose) media, 24-hour exposure to
increasing concentrations of DMAQB-1 that ranged
from 0.5 to 500 nmol/L did not cause an increase
in thymidine incorporation. A slight decrease in
thymidine incorporation was detected, but did not
reach the level of statistical significance. In other
words, the dose-response profile formed a plateau
without evidence of acute toxicity up to and includ-
ing 500 nmol/L as illustrated in Fig 3. The addition
of high glucose to serum-free media produced a
response profile that more closely resembled 1% FBS
media than serum-free media.
Effect in high-glucose and insulin condition.
The experimental condition of insulin combined
with serum-free, high glucose (200 mg/dL glucose)
media was studied to simulate the condition found
in patients with type 2 diabetes. Twenty-four–hour
Fig 3. Dose response in high glucose, serum-free media. Control contained no DMAQB-1.
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exposure to increasing concentrations of DMAQB-1
from 0.5 to 500 nmol/L were added to mild insulin
(100 µU/mL) and moderate insulin (250 µU/mL).
In the case of mild insulin, neither a statistically sig-
nificant increase nor a decrease in thymidine incor-
poration was measured. Also, over the tested range
there was no suggestion of acute toxicity. The mild
insulin response profile is illustrated in Fig 4, A. 
In the case of moderate insulin, there was no sta-
tistically significant increase in thymidine incorpora-
tion. At a DMAQB-1 concentration of 500 nmol/L,
a statistically significant reduction in thymidine
incorporation of 31% was detected (P < .05). As
illustrated in Fig 4, B, the dose-response profile
resembles the profile where 1% FBS was added. 
DISCUSSION
DMAQB-1 was isolated from liquid cultures of a
strain of the fungus Pseudomassaria that was recov-
ered from the leaves of a plant collected near
Kinshasa, Democratic Republic of Congo. With a
variety of techniques, the compound was identified as
a demethylasterriquinone.11 Through a series of
experiments, it was postulated that DMAQB-1 dif-
fused through the cell membrane and interacted with
the intracellular subunit of the IR. The activated IR
then led to the normal tyrosine kinase activation and
subsequent glucose transport. DMAQB-1 was highly
selective for the IR and not for other homologous
protein receptors that are associated with VSMC pro-
liferation, especially the IGF-1 receptor.11
The biochemical model that Zhang et al used to
measure DMAQB-1 specificity and activity relied in
part on two techniques.11 First, they manipulated
Chinese hamster ovary cells to overexpress the
receptor they were studying. Second, they used a
relatively high-dose exposure of DMAQB-1 for a
short period of time. If DMAQB-1 is used clinically
as an oral agent, it is more likely to be administered
to achieve a low effective dose over hours, than a
high dose over minutes. Therefore, to study the
effect on human cells, mimicking as much as possi-
ble human physiology, we used VSMCs with a 24-
hour drug exposure.
To detect a proliferative stimulus from DMAQB-
1, we measured labeled thymidine incorporation in
diabetic VSMCs. In contrast to insulin, 24-hour
exposure to DMAQB-1 lowered thymidine incorpo-
ration even at the lowest dose tested, 0.5 nmol/L.
Severe reduction in thymidine incorporation in nor-
mal glucose, serum-free media became obvious at
500 nmol/L. This reduction is most likely due to
Fig 4. A, Dose response in high glucose, serum-free media with 100 µU/mL of insulin added. B, Dose
response in high glucose, serum-free media with 250 µU/mL insulin added. Asterisk indicates P value < .05
versus control containing no DMAQB-1.
A B
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some form of agent toxicity. Serum-free cell culture
models are convenient for the study of biochemical
signal transduction, but do not replicate the com-
plex milieu of the diabetic patient. However, the dis-
advantage of adding serum to the media stems from
the coadministration of unmeasured and unknown
growth and metabolic factors. The complex compo-
sition of serum may reduce agent toxicity, but may
also reduce the sensitivity of the thymidine incorpo-
ration assay.
To evaluate the potential of serum to reduce the
toxicity of DMAQB-1 thereby extending its thera-
peutic range, we repeated the dose-response experi-
ment adding 1% FBS to the media. This
concentration of FBS increased the baseline thymi-
dine incorporation in all groups and reduced the
toxicity of DMAQB-1 sixfold. It is likely that further
increases in serum content would afford additional
reductions in toxicity. However, the ability to detect
changes in biochemical signal transduction would
also be altered. To minimize agent toxicity and max-
imize experimental sensitivity, we performed the
remaining thymidine incorporation experiments in
serum-free media with a DMAQB-1 concentration
less than or equal to 500 nmol/L.
Zhang et al11 demonstrated effective glucose
uptake using a 20-minute pulse of relatively high con-
centrations of DMAQB-1 in rat primary adipocytes in
the presence of 1% albumin. The concentrations used
were well above the LD50 for serum-free VSMCs we
used in this study. To measure glucose uptake stimu-
lated by nontoxic 24-hour exposures, we used
DMAQB-1 concentrations less than or equal to 100
nmol/L. Within this range, glucose uptake increased
at the lowest dose tested, 0.5 nmol/L. At 5 nmol/L
the increase in glucose uptake became statistically sig-
nificant. Glucose uptake continued to increase and
formed a plateau at 10 nmol/L. Additionally, we mea-
sured the glucose uptake stimulated by insulin to com-
pare the physiologic relevance of DMAQB-1 activity.
To mimic insulin secretion we used a constant insulin
concentration of 100 µU/mL for our comparison.
The glucose uptake stimulated by 100 µU/mL of
insulin was statistically increased over control media.
Furthermore, the level of uptake in this mildly elevated
insulin setting was equal to the uptake stimulated by
10 nmol/L of DMAQB-1. The effectiveness of
DMAQB-1 at these low concentrations, with long
exposures, supports the validity of this model.
Sustained and periodic episodes of hyper-
glycemia are characteristics of diabetics. We have
previously shown that hyperglycemia by itself leads
to increased thymidine incorporation and prolifera-
tion.6,8 However, when increasing concentrations of
DMAQB-1 were added to high glucose, serum-free
media, no statistically significant increase in thymi-
dine incorporation was measured. Furthermore, at
concentrations less than or equal to 500 nmol/L, no
statistically significant decrease in thymidine incor-
poration was measured either. The VSMC response
in the high-glucose condition more closely resem-
bled the response in 1% FBS media than the
response in normal glucose, serum-free media. This
suggests that high glucose also decreases the toxicity
of DMAQB-1.
The combination of hyperglycemia and insulin
resistance is a feature observed in type 2 DM.
Insulin resistance can be overcome by increasing the
concentration of insulin. This may result in the com-
bination of hyperglycemia and hyperinsulinemia. We
have previously shown that the proliferative effects
of hyperglycemia and hyperinsulinemia are additive.8
The magnitude of these metabolic derangements
changes during the course of the disease. Given the
setting of high-glucose concentration, we defined
mild and moderate insulin as 100 µU/mL and 250
µU/mL, respectively. When DMAQB-1 was added
to 100 µU/mL of insulin, no statistically significant
increase or decrease in thymidine incorporation was
measured. When insulin was increased to 250
µU/mL, the only statistically significant change was
a decrease in thymidine incorporation at a DMAQB-
1 concentration of 500 nmol/L.
By using a human infragenicular VSMC culture,
we have shown that a nontoxic range of DMAQB-1
induced an equivalent amount of glucose transport
as compared with insulin. Although DMAQB-1 has
a similar glucose transport effect, it does not have an
insulin-like proliferative effect on human VSMCs in
either the healthy or diabetic environment. With a
lack of an insulin-like proliferative effect on VSMCs,
this orally administered insulin mimetic molecule
may change the management of diabetes and
decrease the development of atherosclerosis in dia-
betic patients.
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DISCUSSION
Dr John J. Castronuovo, Jr (Morristown, NJ). Dr
Weber, congratulations on this well-performed study and
thank you for the opportunity to review the manuscript
before presenting my comments. I certainly needed that
opportunity. This was a fair amount of basic science for me. 
Hyperglycemia and hyperinsulinemia occur in both
type 1 and type 2 diabetes. Glucose and insulin each cause
vascular smooth muscle cell proliferation, and their effect
has been shown to be synergistic in tissue culture by this
group. It may be that these conditions are responsible for
the development of atherosclerosis in diabetic patients or
contribute to the particular distribution of atherosclerotic
lesions seen in the lower extremities of these patients. Your
group has previously shown that the effect of insulin on
vascular smooth muscle cell proliferation is due to stimula-
tion of the insulin-like growth factor receptor by using
monoclonal antibodies to the IGF-1 receptor. You have
shown in this study that an agent that affects insulin sig-
naling pathways in vascular smooth muscle cells could pro-
mote glucose uptake but not cause smooth muscle cell
proliferation. 
The fungal metabolite used in the present study acti-
vates the insulin receptor and has been shown to control
blood glucose in diabetic mice. Unlike insulin, it does not
share cross-reactivity with the IGF-1 receptor. 
I have the following questions: Do any other hypo-
glycemic agents also cause increased vascular smooth mus-
cle cell proliferation? Does this agent have the potential to
replace other oral hypoglycemics or lessen the insulin
requirement of insulin diabetic patients? And lastly, could
the finding that this agent does not stimulate vascular
smooth muscle cell proliferation be due to its toxic effect
on vascular smooth muscle cells in vitro rather than its
inability to stimulate growth factor receptors? 
Dr Michael A. Weber. Thank you very much for your
insightful questions. 
The first question was do other oral hypoglycemic
agents cause smooth muscle cell proliferation? It’s a great
question. Those oral hypoglycemics that stimulate insulin
secretion do potentially cause SMC proliferation. In con-
trast, insulin action enhances just as pioglitazone would
potentially decrease the chance of SMC proliferation. L-
783 has the potential to replace insulin with an oral agent
that does not stimulate proliferation. I think adding an
agent like this will have a very important role in the future. 
The last question was to do with the potential for the
effect to be more of just measuring toxicity rather than
efficacy. We demonstrated the glucose transport, we did
see increasing levels up through the 15 nmol/L or up to
the 5 nmol/L, and then we started to see a plateau and
then a decrease. But we should remember that these
experiments were done in a serum-free condition. The
presence of serum is going to greatly improve any toxicity
that this agent might have. 
Dr K. Craig Kent (New York, NY). This is real excit-
ing data. Insulin is necessary for all of us, but it has
tremendous deleterious effects on smooth muscle cells. As
you mentioned, insulin stimulates smooth muscle cell pro-
liferation. Insulin is also a very potent stimulus of smooth
muscle cell migration and of extracellular matrix protein
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production by smooth muscle cells. Do you have any data
that show the effect of this mimetic on smooth muscle cell
migration and extracellular matrix protein production?
How would you design a model to evaluate this mimetic
versus insulin in animals with regard to intimal hyperplasia?
Dr Weber. Thank you very much for your questions. 
The first one is toward my personal experience with
the migration. I hope to get that experience in the next
weeks to months as we look in the Boyden chambers and
try to measure the migratory effects, if there are any, from
L-783, which I hope there won’t be.
As to the animal model, there are a number of diabetic
mice that you can get, either diabetic knockout mice with
CDK46 knockouts or with streptozotocin-induced dia-
betes in Sprague-Dawley rats or other mouse models. And
it would be a matter of just managing those animals with
insulin versus L-783 versus control, and in giving them an
intimal injury and then measuring that response.
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